Alan J. Lewis, PhD

Alan is CEO of Medistem, which is developing adult stem cell-based therapeutics. He was previously Chairman and CEO of Ambit BioSciences, President and CEO of the Juvenile Diabetes Research Foundation, and CEO of Novocell. He served as CEO of Signal Pharma, which was acquired by Celgene. He then was VP of Research at Wyeth-Ayerst, where he led research efforts in diabetes, cardiovascular, and other diseases. He serves as a Director of BioMarin Pharma and BIOCOM. He holds a Ph.D. in pharmacology from the U. of Wales and completed postdoctoral training at Yale University..